Ethics code: IR.TUMS.TIPS.REC.1403.024
Hosseini M S H, Hajimiri S H H, Dashti-Khavidaki S, Nasiri-Toosi M, Kebriaeezadeh A. Prevalence, Safety Concerns, and Economic Impact of Dietary Supplement Use in Liver Transplant Recipients and Candidates at Imam Khomeini Hospital Complex, Tehran: A Cross-Sectional Study from 2024 to 2025. , Caspian J Intern Med. 2026; 17 (4) :7
URL:
http://caspjim.com/article-1-5054-fa.html
Prevalence, Safety Concerns, and Economic Impact of Dietary Supplement Use in Liver Transplant Recipients and Candidates at Imam Khomeini Hospital Complex, Tehran: A Cross-Sectional Study from 2024 to 2025. ، . 1405; 17 (4) :7
URL: http://caspjim.com/article-1-5054-fa.html
چکیده: (68 مشاهده)
Background: Liver transplantation (LT) is a costly but life-saving intervention for patients with end-stage liver disease. The unregulated use of dietary supplements (DSs) among LT candidates and recipients raises significant safety concerns, including organ toxicity, drug–supplement interactions, and increased risk of graft rejection. This study aimed to assess the prevalence, characteristics, and potential risks associated with DS use in this population.
Methods: This cross-sectional study included LT recipients and candidates referred to a transplant pharmacotherapy clinic between January 1, 2024, and January 29, 2025. Comprehensive medication reviews assessed immunosuppressants, cirrhosis therapies, and dietary supplements, with emphasis on drug-related problems such as organ toxicities, interactions, and immunomodulatory effects. The economic evaluation estimated direct medical cost savings based on the mean monthly expenditures for transplant-related and cirrhosis medications, incorporating the costs of dietary supplements.
Results: Of 100 liver transplant candidates and recipients, 25% used dietary supplements. Among 42 identified products, 70% contained herbal components. Many were associated with potential hepato-, nephro-, or neurotoxicity, and some could alter calcineurin inhibitor levels or exert immunomodulatory effects. Cost analysis revealed that post-transplant patients spent 2.6 times more on DSs than immunosuppressive medications ($37.94 vs. $14.66/month). Pre-transplant patients had nearly equivalent DS and medication costs ($15.60 vs. $17.54/month).
Conclusion: Unnecessary and potentially harmful DS use is common among LT recipients and candidates. These findings underscore the need for enhanced patient education, systematic screening for DS use, and proactive pharmacotherapy management to reduce safety risks, minimize financial burden, and optimize transplant outcomes.
نوع مطالعه:
Original Article |
دریافت: 1404/10/29 | پذیرش: 1405/5/20 | انتشار: 1405/6/18